跳至主要内容
临床试验/NCT02917369
NCT02917369招募中不适用

Integrative Analysis of Large-cell Lung Carcinoma

Shanghai 10th People's Hospital3 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2016年1月最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,000
试验地点
3
主要终点
5 years overall survival

研究概览

简要总结

Integrative analysis of LCLC

详细描述

The investigators will analyzed proteomes of paired normal lung tissues and LCLC with or without liver metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary LCLC carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≤ 75 years with histologically proven LCLC
  • No severe major organ dysfunction
  • World Health Organization (WHO) performance status of 0 or 1
  • No prior cancer chemotherapy

排除标准

  • Severe major organ dysfunction
  • WHO performance status of >1
  • Prior cancer chemotherapy

结局指标

主要结局

5 years overall survival

时间窗: 5 years

次要结局

  • 5 years disease-free survival(5 years)

研究者

发起方
Shanghai 10th People's Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Da Fu

Principal Investigator

Shanghai 10th People's Hospital

研究点 (3)

Loading locations...

相似试验